黑料社

US plans to move COVID vaccines, treatments to private markets in 2023

FILE PHOTO: Vials with Pfizer-BioNTech and Moderna coronavirus disease (COVID-19) vaccine labels are seen in this illustration picture taken March 19, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

FILE PHOTO: Vials with Pfizer-BioNTech and Moderna coronavirus disease (COVID-19) vaccine labels are seen in this illustration picture taken March 19, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

WASHINGTON 鈥 The U.S. government expects its supply of COVID-19 vaccines and antiviral treatments to run out over the next year and is preparing for them to be sold via the commercial market, the Department of Health and Human Services said on Tuesday.

President Joe Biden鈥檚 administration expects to run out of federal funding for buying and distributing COVID-19 vaccines by January, although it has already bought over 170 million doses for a booster campaign later this year, according to a blog post written by Assistant Secretary for Preparedness and Response Dawn O鈥機onnell.

The administration has procured enough of Pfizer鈥檚 antiviral treatment Paxlovid to supply the pills until mid-2023, O鈥機onnell said, but other therapeutics made by Merck & Co and AstraZeneca are likely to be sold on the commercial market sooner.

鈥淥ur goal is to transition procurement and distribution of COVID-19 vaccines and therapeutics from a federally managed system to the commercial marketplace in a thoughtful, well-coordinated manner that leaves no one behind,鈥 she wrote following a meeting with private sector representatives.

Based on current projections, O鈥機onnell said, the supply of AstraZeneca鈥檚 preventative treatment Evusheld will run out in early 2023, followed by Merck鈥檚 antiviral pill Lagevrio (molnupiravir) in the first or second quarter.

The lack of additional Congressional funding means supplies will run out earlier than expected, O鈥機onnell said.

鈥淲e have always intended to transition this work to the commercial market and have been planning for that transition for some time now,鈥 she said. 鈥淯nfortunately, the timeline to make the transition has accelerated over the past six months without additional funds from Congress to support this work,鈥 she said.

Funding is still needed for developing new vaccines, treatments and tests, as well as to manage the transition, she added.

The government also cited a lack of funding on Monday, when it said Americans would no longer be able to order free at-home COVID tests from its COVIDTests.gov website starting next week.

RELATED STORY:
Pass responsibility for COVID vaccine purchases to citizens, Marcos admin urged

Read more...